Merck, Inc.
🇺🇸United States
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2002-11-05
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 800
- Registration Number
- NCT00048594
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2002-11-05
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT00048607
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
Phase 3
Completed
- Conditions
- Leukemia, Myelocytic, AcuteMyelodysplastic SyndromesNeutropenia
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 602
- Registration Number
- NCT00044486
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2002-07-23
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 324
- Registration Number
- NCT00042029
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)
Phase 1
Terminated
- Conditions
- Neoplasms
- First Posted Date
- 2002-07-01
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00040534
Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)
Phase 1
Completed
- Conditions
- Neoplasms
- First Posted Date
- 2002-07-01
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 29
- Registration Number
- NCT00040547
Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)
Phase 2
Terminated
- Conditions
- Bile Duct DiseasesBiliary Tract DiseasesGallbladder DiseasesPancreatitisPancreatic Diseases
- First Posted Date
- 2002-06-21
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 316
- Registration Number
- NCT00040131
PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)
Phase 3
Completed
- Conditions
- Hepatitis C, ChronicFibrosisHepatitisLiver Cirrhosis
- Interventions
- Biological: PegIntron (peginterferon alfa-2b; SCH 54031)
- First Posted Date
- 2002-06-14
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2333
- Registration Number
- NCT00039871
Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye
Phase 3
Completed
- Conditions
- Keratoconjunctivitis Sicca
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 222
- Registration Number
- NCT00037661
Phase III PEG-Intron in HIV-infected Patients (Study P00738)
Phase 3
Completed
- Conditions
- HIV InfectionsAIDS
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 49
- Registration Number
- NCT00035360
© Copyright 2025. All Rights Reserved by MedPath